United States Patent 10,137,200: Minocycline Foam Claims, Patent Scope, and Competitive Landscape

U.S. Patent No. 10,137,200 claims a method of treating acne vulgaris with a surfactant-free, essentially waterless minocycline foam delivered from a pressurized container. The core invention is a specific anhydrous oil-based foam architecture containing minocycline, a C14-C22 fatty alcohol, and one or more fatty acids, waxes, or shea butter components. The patent is most relevant to 4% topical minocycline foam products, including the formulation technology associated with AMZEEQ.

The independent claim is narrow in formulation structure but broad in the permitted oil and excipient universe. A competing product may avoid literal infringement by changing one required formulation element, but the commercial and legal analysis depends on the issued claims, prosecution history, claim construction, and any related patents in the same family.

What does U.S. Patent 10,137,200 protect?

Claim 1 protects a treatment method requiring all of the following elements:

Claim element	Required limitation
Disease	Acne vulgaris
Dosage form	Foam
Delivery	Dispensed from a container
Surfactant	Surfactant-free
Water	Essentially waterless
Polymer	Free of polymeric agent
Main carrier solvent	About 60% to about 95% hydrophobic solvent by carrier weight
Hydrophobic solvent	An oil
Fatty alcohol	About 0.1% to about 20%; C14-C22 carbon chain
Additional structurant	Fatty acid, wax, shea butter, or combination; about 0.1% to about 20%
Active ingredient	Minocycline antibiotic
Petrolatum	No more than 15% by carrier weight
Propellant	Liquefied or compressed gas
Dispensing result	Foam forms upon dispensing

The claim is a combination claim. The accused product must satisfy the limitations collectively. A product containing minocycline in an oil-based foam is not automatically within the claim unless it also has the required fatty alcohol, fatty acid or wax structure, water and polymer exclusions, petrolatum limitation, and dispensing characteristics.

The patent does not claim every topical minocycline formulation. It does not, on the face of the supplied claims, cover:

Oral minocycline;
A non-foam topical gel, cream, lotion, solution, or ointment;
A water-based foam;
A polymer-thickened foam;
A surfactant-containing foam;
A formulation without the specified fatty alcohol;
A formulation using a non-oil primary hydrophobic solvent;
Treatment of a condition other than acne vulgaris, unless another issued claim provides that coverage.

How broad is claim 1 of U.S. Patent 10,137,200?

Claim 1 has broad compositional breadth but multiple narrowing constraints.

The 60%-95% hydrophobic-solvent range is commercially significant. It allows a predominantly oil-based carrier, while the fatty alcohol and wax or fatty acid components can function as consistency, structural, and foam-supporting ingredients. The claim does not require a single named oil. It covers a genus of oils, subject to the requirement that the hydrophobic solvent is an oil.

The fatty alcohol limitation is narrower. The alcohol must have a carbon chain length of 14 to 22 carbons. The dependent claims identify stearyl alcohol, cetyl alcohol, behenyl alcohol, and myristyl alcohol. Short-chain alcohols are expressly excluded in claim 8.

The claim also requires one or more of a fatty acid, wax, shea butter, or mixtures. The wax options in claim 1 include beeswax, hydrogenated castor oil, paraffin wax, and waxes solid at room temperature.

The exclusionary limitations are central:

The composition is essentially waterless.
The composition is free of polymeric agent.
The composition is surfactant-free.
Petrolatum is limited to 15% or less of the carrier.

These limitations distinguish the claimed system from many conventional pharmaceutical foams, which rely on water, surfactants, emulsifiers, polymers, or petrolatum-rich bases.

What do claims 2 through 21 add?

The dependent claims create multiple formulation fallbacks and substantially expand the list of potentially covered carrier materials.

Fatty alcohol and oil limitations

Claims 2, 3, 12, and 13 identify preferred fatty alcohols and hydrophobic solvents. The named fatty alcohols are:

Stearyl alcohol;
Cetyl alcohol;
Behenyl alcohol;
Myristyl alcohol.

The named oils include mineral oils, coconut oil, avocado oil, calendula oil, grape seed oil, jojoba oil, soybean oil, wheat germ oil, MCT oil, cyclomethicone, and octyldodecanol.

Claim 15 expands the oil genus significantly to include plant oils, animal-derived oils, silicone oils, mineral oils, ester oils, essential oils, modified silicone oils, and mixtures.

Wax combinations

Claim 6 narrows the wax to a combination of beeswax and hydrogenated castor oil, with a beeswax-to-hydrogenated-castor-oil ratio of about 1:1 to about 5:1.

Claim 7 requires a fatty-alcohol-to-wax ratio of about 4:1 to about 1:4.

These ratio claims may provide narrower positions for enforcement or validity analysis. They also create design-around opportunities if a competing formulation uses different structural materials or materially different ratios.

Fatty-acid combinations

Claim 4 specifies stearic acid. Claims 11, 20, and 21 establish fatty-acid-to-fatty-alcohol ratio ranges:

Claim	Ratio limitation
Claim 11	Fatty acid to fatty alcohol between about 1:10 and about 10:1
Claim 20	Fatty alcohol to fatty acid about 1:7 to about 16:3
Claim 21	Fatty alcohol to fatty acid about 3:17 to about 2:1

Claim 19 requires all three structural categories: fatty alcohol, fatty acid, and wax.

Minocycline concentration and dosing

Claim 14 specifies minocycline at about 3.5% to about 5% by weight of the carrier. Claim 18 combines once-daily administration with approximately 4% minocycline.

This limitation aligns closely with a 4% topical minocycline foam product. The use of “by weight of the carrier,” rather than necessarily by total finished composition weight, is important. The propellant may be excluded from the denominator depending on the claim construction and formulation accounting.

Is claim 15 technically defective?

As supplied, claim 15 begins: “The composition of claim 1,” although claim 1 is drafted as a method claim. That language creates a dependency and category inconsistency on its face.

The likely explanations are:

The supplied text contains a transcription error;
The issued patent contains a corrected claim category through an amendment or certificate;
Claim 15 was intended to depend on a composition claim from an earlier claim set but was not reproduced accurately.

The legal effect cannot be determined from the claim text alone. The issued patent, prosecution history, and any certificate of correction control. The inconsistency should be checked before relying on claim 15 for validity, infringement, or freedom-to-operate analysis.

What formulations are protected by U.S. Patent 10,137,200?

The strongest commercial embodiment is an anhydrous 4% minocycline foam with an oil-rich carrier, fatty alcohol, fatty acid or wax, and pressurized propellant.

A formulation likely falling within claim 1 would include:

Approximately 4% minocycline by carrier weight;
Approximately 60%-95% liquid oil or other claimed hydrophobic solvent;
Cetyl or stearyl alcohol;
Stearic acid, beeswax, hydrogenated castor oil, or a combination;
A liquefied hydrocarbon or compressed-gas propellant;
No polymeric thickener;
No surfactant;
Minimal or no water;
Petrolatum at 15% or less.

A formulation may fall within narrower claims if it uses stearic acid, beeswax plus hydrogenated castor oil, the specified ratios, or once-daily administration.

How can a generic or competitor design around the patent?

Potential literal design-around paths include:

Design-around approach	Claim limitation targeted
Use a water-containing foam	“Essentially waterless” limitation
Add a polymeric thickener	“Free of polymeric agent” limitation
Use a surfactant or emulsifier	Surfactant-free limitation
Use petrolatum above 15%	Petrolatum ceiling
Use a fatty alcohol outside C14-C22	Fatty-alcohol chain-length limitation
Eliminate fatty acid, wax, or shea butter	Carrier-structurant limitation
Use a non-oil primary solvent	Hydrophobic-solvent limitation
Deliver a cream or gel rather than foam	Foam limitation
Use a non-pressurized package	Container and propellant limitation
Use a different active antibiotic	Minocycline limitation
Treat rosacea rather than acne vulgaris	Method-of-treatment limitation

These routes do not guarantee freedom to operate. Related patents may cover alternative formulations, packaging systems, minocycline concentrations, treatment methods, or manufacturing processes. The doctrine of equivalents may also affect products that make only insubstantial changes.

Is U.S. Patent 10,137,200 an Orange Book patent?

The claim text does not establish Orange Book listing status. Orange Book relevance depends on whether the patent was submitted for an approved drug product and accepted by FDA as a patent claiming the drug substance, drug product, or method of use under 21 C.F.R. § 314.53.

For a topical minocycline foam, the relevant FDA-listed product would be the approved foam product and its holder. A formulation patent may be Orange Book-listed if it claims the approved drug product or an approved method of use. A patent that describes a formulation but does not meet FDA listing criteria may remain legally relevant without appearing in the Orange Book.

Orange Book listing also affects generic entry procedure. A listed patent may support a Paragraph IV certification by an abbreviated new drug application applicant. An unlisted patent does not create the same Orange Book certification pathway, although it may still support patent litigation under ordinary infringement theories.

When does U.S. Patent 10,137,200 lose exclusivity?

The expiration date cannot be determined from the claims supplied. Patent term depends on the earliest effective nonprovisional or international filing date, patent-term adjustment, terminal disclaimers, patent-term extension, and any applicable disclaimer or correction.

The patent issued on November 27, 2018, but the issue date does not establish the expiration date. U.S. utility patents generally receive a term of 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.

For commercial planning, the controlling date is the expiration date recorded for the patent and its relevant family members, not the publication or grant date. Any Orange Book exclusivity period is a separate FDA concept and should not be conflated with patent term.

What is the relevant FDA and commercial landscape?

The principal commercial comparator is AMZEEQ, a 4% topical minocycline foam approved by FDA for the treatment of moderate-to-severe non-nodular acne vulgaris in adults and pediatric patients aged 9 years and older. FDA approved AMZEEQ in October 2019. The product was developed by Foamix Pharmaceuticals and is associated with VYNE Therapeutics following Foamix’s corporate transactions (U.S. Food and Drug Administration, 2019; VYNE Therapeutics, 2024).

A second topical minocycline foam product, ZILXI, contains 1.5% minocycline foam and is approved for inflammatory lesions of rosacea in adults. Its indication is different from acne vulgaris, and its formulation and patent analysis should be conducted separately (U.S. Food and Drug Administration, 2019a).

Product	Active ingredient	Strength	Dosage form	FDA indication	Relevance to Patent 10,137,200
AMZEEQ	Minocycline	4%	Topical foam	Moderate-to-severe acne vulgaris	High, subject to formulation and claim comparison
ZILXI	Minocycline	1.5%	Topical foam	Inflammatory lesions of rosacea	Lower for claim 1’s acne method and 3.5%-5% dependent limitation
Oral minocycline generics	Minocycline	Various	Capsules/tablets	Acne and other infections	Outside the supplied topical foam claims
Other topical acne products	Various	Various	Gel, cream, lotion, foam	Acne vulgaris	Compete therapeutically but may not practice the claimed formulation

Which companies may challenge the patent?

Potential challengers include generic-drug manufacturers seeking approval for a therapeutically equivalent topical minocycline foam and branded companies developing alternative acne delivery systems.

A Paragraph IV challenge would require a generic applicant to address any Orange Book-listed patent identified for the reference product. The applicant could argue that the patent is invalid, unenforceable, or not infringed. A non-infringement strategy would likely focus on the anhydrous, surfactant-free, polymer-free architecture and the precise fatty-alcohol and structurant limitations.

No settlement agreement, Paragraph IV notice, or litigation outcome is established by the supplied claim text. Those matters must be tied to the specific patent family, approved product, ANDA filings, and court docket.

How strong is the patent estate?

Patent strength is best assessed across five dimensions:

Claim coverage: Claim 1 covers the core combination of acne treatment, minocycline, an oil-rich carrier, fatty alcohol, structural lipid or wax, and pressurized foam delivery.
Design-around exposure: The claim contains several binary exclusions that a competitor may target.
Dependent-claim redundancy: Claims 2, 3, 12, and 13 overlap materially in fatty alcohol and oil definitions. Redundancy can preserve coverage but may create prosecution-history and obviousness issues.
Functional differentiation: The patent focuses on composition architecture and dispensing behavior rather than minocycline alone.
Family coverage: Related patents may separately protect formulation, manufacturing, container, concentration, or method-of-use features.

The strongest infringement position would generally involve a product that closely mirrors a 4% oil-based, anhydrous minocycline foam using cetyl or stearyl alcohol and beeswax, hydrogenated castor oil, or stearic acid. The weakest position would involve a water-based, polymer-containing, surfactant-stabilized product with a different dosage form or non-minocycline active.

Key Takeaways

U.S. Patent 10,137,200 is directed to a surfactant-free, essentially waterless minocycline foam for acne vulgaris.
Claim 1 requires an oil-based carrier, C14-C22 fatty alcohol, fatty acid, wax, or shea butter, minocycline, propellant, and foam formation.
The patent excludes or limits several conventional formulation strategies, including polymers, significant water, surfactants, and petrolatum above 15%.
Claims 6, 7, 11, 14, 18, 20, and 21 add commercially relevant wax, ratio, concentration, and dosing limitations.
The claim set is relevant to 4% topical minocycline foam products, particularly AMZEEQ-type formulations.
Claim 15, as supplied, contains a method/composition dependency inconsistency that requires review of the issued record.
Patent expiration, Orange Book listing, Paragraph IV activity, litigation, and settlement status cannot be determined from the claim text alone.
Generic risk is highest for products that reproduce the anhydrous oil-rich foam structure and lowest for products using water, polymers, surfactants, different structural excipients, or a non-foam dosage form.

FAQs

Does U.S. Patent 10,137,200 cover all 4% minocycline products?

No. The product must satisfy the claim’s formulation, packaging, foam, excipient, and acne-treatment limitations. A 4% concentration alone is insufficient.

Can a water-based minocycline foam infringe this patent?

A water-based product would face a substantial literal non-infringement position against the “essentially waterless” limitation. Other patents may still apply.

Does the patent cover minocycline foam for rosacea?

The supplied independent claim is limited to treating acne vulgaris. The rosacea indication associated with ZILXI is not within claim 1 as written.

Are fatty alcohols required for infringement?

Yes. Claim 1 requires at least one fatty alcohol having a carbon chain length of 14 to 22 carbons. The dependent claims narrow the choice to specified fatty alcohols but do not broaden that requirement.

Can a competitor replace beeswax with another excipient?

Potentially, depending on the replacement and the resulting formulation. Claim 1 covers fatty acids, waxes, shea butter, and mixtures, so replacing beeswax with another claimed wax may not avoid infringement.

References

Food and Drug Administration. (2019). AMZEEQ (minocycline) topical foam, 4%: Prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2019a). ZILXI (minocycline) topical foam, 1.5%: Prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Patent No. 10,137,200. (2018). Minocycline foam compositions and methods of use. United States Patent and Trademark Office.
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure: Patent term adjustment and patent term extension. U.S. Department of Commerce.
VYNE Therapeutics Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Journey	AMZEEQ	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	212379-001	Oct 18, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF NON-NODULAR ACNE VULGARIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010302350	⤷ Start Trial
Australia	2015224534	⤷ Start Trial
Brazil	112012007473	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,137,200

Which drugs does patent 10,137,200 protect, and when does it expire?

Summary for Patent: 10,137,200